ReviewIntensive care medicine2020
Phenotypes and personalized medicine in the acute respiratory distress syndrome.
Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it, 202 citations in OpenAlex.
- Integrative omics provide biological and clinical insights into acute respiratory distress syndrome.Intensive care medicine · 2021Pooled it
- Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.Intensive care medicine · 2025Trial
- A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19.American journal of respiratory and critical care medicine · 2023Trial
- Longitudinal phenotypes in patients with acute respiratory distress syndrome: a multi-database study.Critical care (London, England) · 2022Trial
- One-year patient outcomes based on lung morphology in acute respiratory distress syndrome: secondary analysis of LIVE trial.Critical care (London, England) · 2022Trial
- Trial
- Trial
- Lung- and diaphragm-protective mechanical ventilation in acute respiratory distress syndrome.Intensive care medicine · 2026Review
- Research trends and cellular targets of NF-κB pathway in acute lung injury [2005-2024]: a combined bibliometric analysis and systematic review.Journal of thoracic disease · 2026Article
- Phillygenin protects against lipopolysaccharide-induced acute lung injury by acting as a PXR agonist via NF-κB inhibition.Scientific reports · 2026Article
- Review
- The landscape of protein post-translational modifications in the pathogenesis of acute respiratory distress syndrome.Journal of thoracic disease · 2026Review
- Machine learning phenotypes and heterogeneous albumin effects in cirrhotic AKI: a causal inference study.Internal and emergency medicine · 2026Article
- Prognostic significance of the endothelial activation and stress index in acute respiratory distress syndrome: a retrospective cohort study.Scientific reports · 2026Article
- Myeloid-specific Becn1 deficiency elicits spontaneous pulmonary injury and exacerbates acute lung injury.Respiratory research · 2026Article
- Review
- Improving retrospective ARDS case-finding using a simple 72-h physiologic persistence rule.Intensive care medicine experimental · 2026Article
- Characterizing heterogeneity and subphenotyping acute respiratory distress syndrome with computed tomography.Intensive care medicine experimental · 2026Review
- Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS.BMJ open respiratory research · 2026Article
- EIT-based ventilation phenotypes of left-to-right asymmetry and ventral-to-dorsal center in PEEP titration in ARDS.Respiratory research · 2026Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 4 countries.
Funding
Abstract
Although the acute respiratory distress syndrome (ARDS) is well defined by the development of acute hypoxemia, bilateral infiltrates and non-cardiogenic pulmonary edema, ARDS is heterogeneous in terms of clinical risk factors, physiology of lung injury, microbiology, and biology, potentially explaining why pharmacologic therapies have been mostly unsuccessful in treating ARDS. Identifying phenotypes of ARDS and integrating this information into patient selection for clinical trials may increase the chance for efficacy with new treatments. In this review, we focus on classifying ARDS by the associated clinical disorders, physiological data, and radiographic imaging. We consider biologic phenotypes, including plasma protein biomarkers, gene expression, and common causative microbiologic pathogens. We will also discuss the issue of focusing clinical trials on the patient's phase of lung injury, including prevention, administration of therapy during early acute lung injury, and treatment of established ARDS. A more in depth understanding of the interplay of these variables in ARDS should provide more success in designing and conducting clinical trials and achieving the goal of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.